Literature DB >> 34067306

Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment.

André Lee1,2, Jabreel Al-Sarea3, Eckart Altenmüller1.   

Abstract

Botulinum toxin (BoTX) is the standard treatment for task-specific dystonias (TSDs) such as musician's dystonia (MD). Our aim was to assess the long-term changes in BoTX treatment in a highly homogeneous and, to our knowledge, largest group of MD patients with respect to the following parameters: (1) absolute and (2) relative BoTX dosage, (3) number of treated muscles, and (4) inter-injection interval. We retrospectively assessed a treatment period of 20 years in 233 patients, who had received a cumulative dose of 68,540 MU of BoTX in 1819 treatment sessions, performed by two neurologists. Nonlinear correlation was used to analyze changes in the parameters over the course of repeated treatments. Post-hoc we applied a median-split to classify two subgroups (high-BoTX, low-BoTX) depending on the total amount of BoTX needed during treatment. Across all patients, we found a decrease of dosage for the first approximately 25 treatments with an increase afterwards. The number of muscles and inter-injection intervals increased with time with a discrete decrease of inter-injection intervals after about 35 treatments. Subgroup differences were observed in the amount of BoTX and inter-injection intervals, with continuously increasing inter-injection intervals and decreasing BoTX dosage in the low-BTX group. Both groups showed a continuously increasing number of injected muscles. In summary, we found nonlinear changes of BoTX dosage and inter-injection intervals and a continuously increasing number of injected muscles with treatment duration in TSD-patients. Furthermore, we, for the first time, identified two subgroups with distinct differences. Increasing inter-injection intervals and decreasing BoTX dosages in the low-BoTX group indicated improvement of symptoms with continued treatment. Continually increasing BoTX dosages with unchanged inter-injection intervals in the high-BoTX group indicated deterioration.

Entities:  

Keywords:  botulinum toxin A; inter-injection interval; long term treatment; musician’s dystonia; nonlinear correlation; task-specific dystonia

Year:  2021        PMID: 34067306     DOI: 10.3390/toxins13060371

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  33 in total

1.  Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.

Authors:  G-Y R Hsiung; S K Das; R Ranawaya; A-L Lafontaine; O Suchowersky
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

2.  [Changes in dose and injection pattern in the botulinum toxin long-term therapy of facial dyskinesis].

Authors:  R Laskawi; A Niemczewska; S Schneider; J Winterhoff; C Beutner; S Rohrbach
Journal:  Laryngorhinootologie       Date:  2013-12-09       Impact factor: 1.057

Review 3.  Botulinum toxin therapy of writer's cramp.

Authors:  C P Das; D Dressler; M Hallett
Journal:  Eur J Neurol       Date:  2006-02       Impact factor: 6.089

4.  Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).

Authors:  Djamel Bensmail; Angelika Hanschmann; Jörg Wissel
Journal:  J Med Econ       Date:  2014-06-12       Impact factor: 2.448

5.  IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.

Authors:  Virgilio Gerald H Evidente; Daniel Truong; Joseph Jankovic; Cynthia L Comella; Susanne Grafe; Angelika Hanschmann
Journal:  J Neurol Sci       Date:  2014-08-10       Impact factor: 3.181

6.  Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.

Authors:  Joseph Jankovic; Cynthia Comella; Angelika Hanschmann; Susanne Grafe
Journal:  Mov Disord       Date:  2011-04-22       Impact factor: 10.338

7.  Long-term botulinum toxin efficacy, safety, and immunogenicity.

Authors:  Nicte I Mejia; Kevin Dat Vuong; Joseph Jankovic
Journal:  Mov Disord       Date:  2005-05       Impact factor: 10.338

8.  Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.

Authors:  Moshe Snir; Dov Weinberger; Dan Bourla; Orhit Kristal-Shalit; Gad Dotan; Ruth Axer-Siegel
Journal:  Am J Ophthalmol       Date:  2003-07       Impact factor: 5.258

Review 9.  Task-specific dystonias: a review.

Authors:  Diego Torres-Russotto; Joel S Perlmutter
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.

Authors:  Katja Kollewe; Bahram Mohammadi; Steffen Köhler; Heidrun Pickenbrock; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2014-07-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.